BCIQ Profiles

Target Profile Report
0708 Keymed IPO
BioCentury & Getty Images


Keymed’s first-day valuation tops $2B after pricing Hong Kong IPO

Jul 8, 2021 | 8:48 PM GMT

Public investors welcomed Keymed with a warm reception on the Hong Kong stock exchange, signaling confidence in a pipeline that includes the Chinese biotech’s potential Dupixent competitor.

In its first

Read the full 513 word article

How to gain access

Continue reading with a
two-week free trial.